GlassScriptPhysician profile
Michael D Kommor
NPI 1760453518
$1,897.68
in general payments reported to CMS, 2019-2025
33 companies · $538 in 2025
The $538 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $30.72 · 2021: $92.60 · 2022: $121 · 2023: $372 · 2024: $609 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457 · Education: $62.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,457.39 |
| Education | $62.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $539.51 | 2019-2025 | |
| Celgene Corporation | $266.86 | 2021-2025 | Reblozyl, Pomalyst, Breyanzi |
| Astrazeneca Pharmaceuticals LP | $161.75 | 2021-2025 | Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $116.25 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $104.85 | 2019-2024 | |
| Abbvie INC. | $68.35 | 2024-2025 | |
| Astellas Pharma US INC | $63.79 | 2025 | Vyloy |
| Genentech USA, INC. | $39.95 | 2021-2023 | Venclexta, Lunsumio |
| Daiichi Sankyo INC. | $37.94 | 2024-2025 | Injectafer, Enhertu |
| Gilead Sciences, INC. | $37.85 | 2019-2025 | Trodelvy |
| Kite Pharma, INC. | $35.28 | 2020-2021 | |
| Fennec Pharmaceuticals, INC. | $35.03 | 2023-2024 | Pedmark |
| Cti Biopharma Corp. | $32.49 | 2023 | Vonjo |
| Glaxosmithkline, LLC. | $31.74 | 2024 | Ojjaara |
| Ipsen Biopharmaceuticals, INC | $30.74 | 2024-2025 | Onivyde, Tazverik |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $25.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.53 | 2024 | Libtayo |
| Foundation Medicine, INC. | $21.62 | 2019 | |
| Sun Pharmaceutical Industries INC. | $20.72 | 2023 | Yonsa, Odomzo |
| Novo Nordisk INC | $20.38 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $19.39 | 2025 | Sancuso |
| Beigene USA, INC. | $17.95 | 2022 | |
| Pharmaessentia USA Corporation | $17.65 | 2022 | |
| Adc Therapeutics America, INC. | $17.06 | 2024 | |
| Stemline Therapeutics INC. | $16.75 | 2020 | |
| Agios Pharmaceuticals, INC. | $16.53 | 2023 | Pyrukynd |
| Genmab U.S., INC. | $14.67 | 2021 | |
| Pharmacosmos Therapeutics INC. | $14.17 | 2023 | Monoferric |
| Seagen INC. | $13.48 | 2022 | |
| Adaptive Biotechnologies Corporation | $12.86 | 2023 | Clonoseq |
| Global Blood Therapeutics, INC. | $12.65 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $10.89 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kommor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.